● PRNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents and marketable…
● PRNewsWireOct 14, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and commercialization, as it plans to in…
● PRNewsWireOct 6, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical c…
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling
Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) shares fell 4.5% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $43.20 and last traded at $43.4350. 62,397 s…
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…
● PRNewsWireSep 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics to Present at Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule …
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-comp…
● PRNewsWireAug 31, 2026 · 18:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule …
BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN
BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,359,704 shar…
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloi…
Article counts from the last market-wide feed page, across every symbol we track and not just ELVN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.